SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-185058
Filing Date
2022-06-29
Accepted
2022-06-29 16:10:57
Documents
13
Period of Report
2022-06-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d322412d8k.htm   iXBRL 8-K 25057
2 EX-99.1 d322412dex991.htm EX-99.1 9879
  Complete submission text file 0001193125-22-185058.txt   164288

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA antx-20220629.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20220629_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20220629_pre.xml EX-101.PRE 11724
7 EXTRACTED XBRL INSTANCE DOCUMENT d322412d8k_htm.xml XML 3438
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 221054783
SIC: 2834 Pharmaceutical Preparations